Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories

Overview

Journal J Pers Med

Date 2023 Oct 27

PMID 37888038

Authors

Marco Sposito

Lorenzo Belluomini

Letizia Pontolillo

Daniela Tregnago

Ilaria Trestini

Jessica Insolda

Alice Avancini

Michele Milella

Emilio Bria

Luisa Carbognin

Sara Pilotto

Affiliations

Soon will be listed here.

Abstract

Targeted therapy (TT) has revolutionized cancer treatment, successfully applied in various settings. Adjuvant TT in resected early-stage gastrointestinal stromal tumors (GIST), melanoma, non-small cell lung cancer (NSCLC), and breast cancer has led to practice-changing achievements. In particular, standard treatments include BRAF inhibitors for melanoma, osimertinib for NSCLC, hormone therapy or HER2 TT for breast cancer, and imatinib for GIST. Despite the undeniable benefit derived from adjuvant TT, the optimal duration of TT and the appropriate managing of the relapse remain open questions. Furthermore, neoadjuvant TT is emerging as valuable, particularly in breast cancer, and ongoing studies evaluate TT in the perioperative setting for early-stage NSCLC. In this review, we aim to collect and describe the large amount of data available in the literature about adjuvant TT across different histologies, focusing on epidemiology, major advances, and future directions.

Citing Articles

Design, Synthesis, and Evaluation of Trihalomethyl Ketone Derivatives of Neocarzilin A as Improved Antimetastatic Agents.

Moriarty N, Benton A, Gartenhaus L, Nelson A, Harper H, McMahan C ACS Bio Med Chem Au. 2024; 4(6):331-341.

PMID: 39712208 PMC: 11659896. DOI: 10.1021/acsbiomedchemau.4c00087.

References

Joensuu H, Eriksson M, Hall K, Hartmann J, Pink D, Schutte J . One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012; 307(12):1265-72. DOI: 10.1001/jama.2012.347. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Conte P, Frassoldati A, Bisagni G, Brandes A, Donadio M, Garrone O . Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. Ann Oncol. 2018; 29(12):2328-2333. DOI: 10.1093/annonc/mdy414. View

Caparica R, Lambertini M, Ponde N, Fumagalli D, de Azambuja E, Piccart M . Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. Ther Adv Med Oncol. 2019; 11:1758835919827714. PMC: 6393951. DOI: 10.1177/1758835919827714. View

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S . Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279(5350):577-80. DOI: 10.1126/science.279.5350.577. View

Li N, Ou W, Ye X, Sun H, Zhang L, Fang Q . Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study. Ann Surg Oncol. 2014; 21(6):2091-6. DOI: 10.1245/s10434-014-3586-9. View

Herbst R, Wu Y, John T, Grohe C, Majem M, Wang J . Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023; 41(10):1830-1840. PMC: 10082285. DOI: 10.1200/JCO.22.02186. View

Gnant M, Dueck A, Frantal S, Martin M, Burstein H, Greil R . Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2021; 40(3):282-293. PMC: 10476784. DOI: 10.1200/JCO.21.02554. View

Goss P, Smith I, OShaughnessy J, Ejlertsen B, Kaufmann M, Boyle F . Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2012; 14(1):88-96. DOI: 10.1016/S1470-2045(12)70508-9. View

10.

Mamounas E, Untch M, Mano M, Huang C, Geyer Jr C, von Minckwitz G . Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. Ann Oncol. 2021; 32(8):1005-1014. DOI: 10.1016/j.annonc.2021.04.011. View

11.

Amaria R, Prieto P, Tetzlaff M, Reuben A, Andrews M, Ross M . Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018; 19(2):181-193. DOI: 10.1016/S1470-2045(18)30015-9. View

12.

Buzdar A, Ibrahim N, Francis D, Booser D, Thomas E, Theriault R . Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23(16):3676-85. DOI: 10.1200/JCO.2005.07.032. View

13.

Tuveson D, Willis N, Jacks T, Griffin J, Singer S, Fletcher C . STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001; 20(36):5054-8. DOI: 10.1038/sj.onc.1204704. View

14.

Farago A, Taylor M, Doebele R, Zhu V, Kummar S, Spira A . Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an Gene Fusion. JCO Precis Oncol. 2018; 2018. PMC: 6132056. DOI: 10.1200/PO.18.00037. View

15.

Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M . Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial. JAMA Oncol. 2018; 4(9):1199-1206. PMC: 6143012. DOI: 10.1001/jamaoncol.2018.1380. View

16.

Tovari J, Vari-Mezo D, Surguta S, Ladanyi A, Kigyos A, Cserepes M . Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets. Cells. 2023; 12(14). PMC: 10377807. DOI: 10.3390/cells12141919. View

17.

Mayer E, Dueck A, Martin M, Rubovszky G, Burstein H, Bellet-Ezquerra M . Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021; 22(2):212-222. DOI: 10.1016/S1470-2045(20)30642-2. View

18.

Shaw A, Ou S, Bang Y, Camidge D, Solomon B, Salgia R . Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 371(21):1963-71. PMC: 4264527. DOI: 10.1056/NEJMoa1406766. View

19.

Debiec-Rychter M, Sciot R, Cesne A, Schlemmer M, Hohenberger P, van Oosterom A . KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006; 42(8):1093-103. DOI: 10.1016/j.ejca.2006.01.030. View

20.

Feng S, Wang Y, Cai K, Wu H, Xiong G, Wang H . Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy. PLoS One. 2015; 10(10):e0140794. PMC: 4608803. DOI: 10.1371/journal.pone.0140794. View